Overview
Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from the ACTH(4-7) fragment, to which a Pro-Gly-Pro tripeptide confers enzymatic stability. It is devoid of corticotropic activity.
Mechanism of action
In research, Semax increases BDNF and NGF expression (CREB pathway), modulates dopaminergic and serotonergic neurotransmission, and displays neuroprotective properties. In the rat hippocampus, a single administration was associated with an approximately 1.4× increase in BDNF and 1.6× in TrkB phosphorylation.
Research context
Semax is approved in Russia for ischaemic stroke and certain cognitive disorders. It is approved neither in the EU nor in the United States.
Quality assurance
- Purity ≥ 99 % verified by HPLC
- Certificate of Analysis (COA) available per batch
- Traceability: unique batch number on every vial
Format & handling
Presentation: lyophilised powder, 5 mg / vial · Reconstitution: bacteriostatic water · Storage: refrigerate the lyophilisate; after reconstitution, keep cold and protected from light.
References
- « Semax, an analog of ACTH(4–10)… regulates BDNF and trkB expression in the rat hippocampus », Brain Research.





Reviews
There are no reviews yet.